EGFR and non-small cell lung carcinoma: In the FLAURA2 trial, patients with EGFR-mutated advanced NSCLC who were given osimertinib plus a chemotherapy regimen experienced significantly longer PFS than those undergoing osimertinib monotherapy as first-line treatment [25.5 months versus 16.7 months; HR of 0.62 (95% CI, 0.49 to 0.79); p < 0.001] [22].